Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Moleculin Biotech completed enrollment of 89 subjects in Part A of the pivotal Phase 2/3 MIRACLE trial, keeping a comprehensive Part A data readout on track for Q1 2027.Key Highlights:Original SEC Filing: Moleculin Biotech, Inc. [ MBRX ] - 8-K - Sep. 29, 2026This is an AI-powered summary. It may co…
Moleculin Biotech said it has closed Part A enrollment in its Phase 2/3 MIRACLE trial of Annamycin plus cytarabine for relapsed or refractory AML; Part A enrolled 89 patients and a comprehensive data readout is planned for Q1 2027.